Alyssa Obermayer

Ms. Alyssa Obermayer

Moffitt Cancer Center & Research Institute
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Science Immunology
Verified
Journal Article
Closed access
EHEric Y. Helm
Eric Y. Helm
Tomas ZelenkaTomas Zelenka
Tomas Zelenka
VCValeriu B. Cismasiu
Valeriu B. Cismasiu
SIShamima Islam
Shamima Islam
LSLeonardo Silvane
Leonardo Silvane
DADorina Avram
Dorina Avram
The networks of transcription factors (TFs) that control intestinal-resident memory CD8 + T (T RM ) cells, including multipotency and effector programs, are poorly understood. In this work, we investigated the role of the TF Bcl11b in T RM cells during infection with Listeria monocytogenes using mice with post-activation, conditional deletion of Bcl11b in CD8 + T cells. Conditional deletion of Bcl11b resulted in increased numbers of intestinal T RM cells and their precursors as well as decreased splenic effector and circulating memory cells and precursors. Loss of circulating memory cells was in part due to increased intestinal homing of Bcl11b −/− circulating precursors, with no major alterations in their programs. Bcl11b −/− T RM cells had altered transcriptional programs, with diminished expression of multipotent/multifunctional (MP/MF) program genes, including Tcf7 , and up-regulation of the effector program genes, including Prdm1. Bcl11b also limits the expression of Ahr, another TF with a role in intestinal CD8 + T RM cell differentiation. Deregulation of T RM programs translated into a poor recall response despite T RM cell accumulation in the intestine. Reduced expression of MP/MF program genes in Bcl11b −/− T RM cells was linked to decreased chromatin accessibility and a reduction in activating histone marks at these loci. In contrast, the effector program genes displayed increased activating epigenetic status. These findings demonstrate that Bcl11b is a frontrunner in the tissue residency program of intestinal memory cells upstream of Tcf1 and Blimp1, promoting multipotency and restricting the effector program.

15 September 2023 in Cell Reports
Verified
Journal Article
Open access
MNMathieu Neault
Mathieu Neault
CLCharles-Étienne Lebert-Ghali
Charles-Étienne Lebert-Ghali
MFMarilaine Fournier
Marilaine Fournier
CCCaroline Capdevielle
Caroline Capdevielle
EGElizabeth A.R. Garfinkle
Elizabeth A.R. Garfinkle
FMFrédérick A. Mallette
Frédérick A. Mallette
Pediatric acute megakaryoblastic leukemia (AMKL) is an aggressive blood cancer associated with poor therapeutic response and high mortality. Here we describe the development of CBFA2T3-GLIS2-driven mouse models of AMKL that recapitulate the phenotypic and transcriptional signatures of the human disease. We show that an activating Ras mutation that occurs in human AMKL increases the penetrance and decreases the latency of CBF2AT3-GLIS2-driven AMKL. CBFA2T3-GLIS2 and GLIS2 modulate similar transcriptional networks. We identify the dominant oncogenic properties of GLIS2 that trigger AMKL in cooperation with oncogenic Ras. We find that both CBFA2T3-GLIS2 and GLIS2 alter the expression of a number of BH3-only proteins, causing AMKL cell sensitivity to the BCL2 inhibitor navitoclax both in vitro and in vivo, suggesting a potential therapeutic option for pediatric patients suffering from CBFA2T3-GLIS2-driven AMKL.

26 November 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
TSTimothy I Shaw
Timothy I Shaw
SPStanley Pounds
Stanley Pounds
Xueyuan CaoXueyuan Cao
Xueyuan Cao
JMJing Ma
Jing Ma
GPGustavo Palacios
Gustavo Palacios
VLVasiliki Leventaki
Vasiliki Leventaki

19 May 2025 in Blood Advances
Verified
Journal Article
Open access
WGWael Gamal
Wael Gamal
NGNienke B. Goedhart
Nienke B. Goedhart
HSHelga Simon-Molas
Helga Simon-Molas
MMMelanie Mediavilla-Varela
Melanie Mediavilla-Varela
AUAngimar Uriepero-Palma
Angimar Uriepero-Palma
AKArnon P. Kater
Arnon P. Kater
An unmet clinical need in chronic lymphocytic leukemia (CLL) is emerging due to the rapidly expanding group of patients with double refractory (Bruton's tyrosine kinase- and B-cell lymphoma 2-inhibitor) disease. So far, autologous T-cell–based therapies, including chimeric antigen receptor (CAR) T cells, have limited success in CLL, which has been attributed to an acquired CLL-mediated T-cell dysfunction and subset skewing toward effector cells at the expense of memory formation. T-cell responses rely on dynamic metabolic processes, particularly mitochondrial fitness. Although mitochondrial disruptions have been observed in solid tumor–infiltrating lymphocytes, their impact on T-cell immunity in lymphoproliferative disorders is unknown. Recent findings indicate that mitochondrial mass in CAR T cells correlates with CLL clinical outcomes. This prompted our investigation into the mitochondrial fitness in CLL T cells. Integrated metabolic and functional analyses revealed impaired, depolarized mitochondria across all T-cell subsets in untreated patients with CLL, leading to further ex vivo and in vivo mouse studies on the underlying signaling alterations. Multiomics profiling of transcriptome and epigenome revealed significant alterations in mitochondrial signaling, diminished adenosine monophosphate-activated protein kinase and autophagy activity, and upregulated glycolysis coupled with hyperactivation of Akt. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway during CLL T-cell culture induced metabolic reprogramming, enhancing mitochondrial activity, expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha, and memory differentiation. Underscoring clinical relevance, supplementation with the PI3Kδ inhibitor idelalisib during CAR T-cell manufacturing improved persistence and long-term leukemia-free remissions in an immunocompetent murine model. Our study suggests that modulating the abnormal CLL T-cell metabolism can enhance the efficacy of autologous T-cell therapies.

8 February 2022 in Biology
Verified
Journal Article
Open access
PDF file
AOAlyssa Obermayer
Alyssa Obermayer
LDLi Dong
Li Dong
QHQianqian Hu
Qianqian Hu
MGMichael Golden
Michael Golden
JNJerald D. Noble
Jerald D. Noble
TSTimothy I Shaw
Timothy I Shaw
High-throughput transcriptomic and proteomic analyses are now routinely applied to study cancer biology. However, complex omics integration remains challenging and often time-consuming. Here, we developed DRPPM-EASY, an R Shiny framework for integrative multi-omics analysis. We applied our application to analyze RNA-seq data generated from a USP7 knockdown in T-cell acute lymphoblastic leukemia (T-ALL) cell line, which identified upregulated expression of a TAL1-associated proliferative signature in T-cell acute lymphoblastic leukemia cell lines. Next, we performed proteomic profiling of the USP7 knockdown samples. Through DRPPM-EASY-Integration, we performed a concurrent analysis of the transcriptome and proteome and identified consistent disruption of the protein degradation machinery and spliceosome in samples with USP7 silencing. To further illustrate the utility of the R Shiny framework, we developed DRPPM-EASY-CCLE, a Shiny extension preloaded with the Cancer Cell Line Encyclopedia (CCLE) data. The DRPPM-EASY-CCLE app facilitates the sample querying and phenotype assignment by incorporating meta information, such as genetic mutation, metastasis status, sex, and collection site. As proof of concept, we verified the expression of TP53 associated DNA damage signature in TP53 mutated ovary cancer cells. Altogether, our open-source application provides an easy-to-use framework for omics exploration and discovery.

1 December 2021 in Current Protein & Peptide Science
Verified
Journal Article
Closed access
PDF file
AOAlyssa Obermayer
Alyssa Obermayer
Vladimir N. UverskyVladimir N. Uversky
Vladimir N. Uversky